Wealth Alliance LLC Has $2.77 Million Position in Merck & Co., Inc. $MRK

Wealth Alliance LLC grew its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 33.4% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,028 shares of the company’s stock after acquiring an additional 5,760 shares during the period. Wealth Alliance LLC’s holdings in Merck & Co., Inc. were worth $2,770,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Kingdom Financial Group LLC. acquired a new stake in Merck & Co., Inc. during the fourth quarter valued at $25,000. Abound Financial LLC acquired a new position in Merck & Co., Inc. in the 4th quarter worth about $26,000. Prosperity Bancshares Inc purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $26,000. High Note Wealth LLC raised its stake in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $31,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced initial access plans for alimatravir, its investigational once-monthly oral HIV PrEP in Phase 3 development, and said it has signed voluntary licensing agreements covering 129 countries. That broad access strategy could support adoption in large international markets if the drug is approved. Article Title
• Neutral Sentiment: Merck also issued a company release on the same alimatravir access plan, reinforcing that the program is moving forward and that it is trying to expand availability in regions that account for most new HIV diagnoses globally. Article Title
• Neutral Sentiment: Traders also bought a high volume of Merck call options, which may reflect rising bullish speculation around the stock and the HIV pipeline, but it does not by itself change fundamentals. Article Title
• Negative Sentiment: Par Health launched the first generic version of Janumet XR in the U.S., which may pressure Merck’s diabetes-related sales and adds another competitive headwind for an established product. Article Title

Merck & Co., Inc. Stock Performance

MRK opened at $131.06 on Friday. The company has a market cap of $323.68 billion, a PE ratio of 36.92, a price-to-earnings-growth ratio of 5.18 and a beta of 0.19. The stock has a 50-day moving average of $121.67 and a 200-day moving average of $117.71. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $131.74. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same quarter in the prior year, the firm posted $2.22 EPS. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities research analysts forecast that Merck & Co., Inc. will post 2.74 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th were issued a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.6%. The ex-dividend date was Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 95.77%.

Analysts Set New Price Targets

Several brokerages recently commented on MRK. Wells Fargo & Company boosted their price target on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, July 8th. Citigroup started coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price for the company. Bank of America boosted their target price on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Weiss Ratings lowered shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Finally, CICC Research began coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.94.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.